Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Bristol-Myers Squibb CompanyNYSE: BMY
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $3.32B rose 152.6% year over year, ahead of the +83.1% change in trailing-twelve-month net income. Sequentially, it rose 23.8% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.
Context
- Net income amounted to 14.6% of revenue in FY2025, down 3.9 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 19 analysts of $13.22B (+87.4%) for the fiscal year ending Dec 2026, a slowdown from the +179.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.32B+23.8% QoQ
- Last fiscal yearDec 2025
- $7.06B+179.0% YoY
- LTMJun 2026
- $9.27B+83.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +152.6% | +2.8% | -149.8 pp |
| 1 year | +179.0% | +87.4% | -91.6 pp |
| 3-year CAGR | +3.6% | +15.6% | +12.0 pp |
| 5-year CAGR | +7.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 7.06B USD
- Year-over-year change
- +179.0%
- 4-year CAGR
- +0.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.06B | +179.0% |
| FY2024 | 2024-12-31 | (8.93B) | -211.1% |
| FY2023 | 2023-12-31 | 8.04B | +26.7% |
| FY2022 | 2022-12-31 | 6.35B | -9.5% |
| FY2021 | 2021-12-31 | 7.01B | — |
Net Income vs competitors
How BMY compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +83.1% is the 2nd highest of 11, against a peer median of +4.5%.
- Net income amounts to 18.9% of revenue for BMY, versus a peer median of 17.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $26.71B USD | +93.6% | +49.0% | 33.5% | |
| LTM Sep 2026 | $16.1B USD | -35.9% | +14.3% | 16.2% | |
| LTM Jun 2026 | $12.76B USD | -6.4% | +32.5% | 22.9% | |
| LTM Sep 2026 | $11.82B USD | +15.4% | +59.9% | 19.0% | |
| LTM Jun 2026 | $9.27B USD | +83.1% | +3.6% | 18.9% | |
| LTM Jun 2026 | $8.74B USD | +32.1% | +5.6% | 22.9% | |
| LTM Jun 2026 | $6.32B USD | +66.4% | -29.1% | 9.8% | |
| LTM Jun 2026 | £5.62B GBP | +41.0% | +0.6% | 16.9% | |
| LTM Jun 2026 | $5.24B USD | -17.0% | +22.8% | 17.2% | |
| LTM Jun 2026 | $4.37B USD | -59.4% | -37.2% | 6.9% | |
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| Peer median (excluding BMY) | — | +4.5% | +11.1% | 17.1% | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.01B | 6.35B | 8.04B | (8.93B) | 7.06B |
| Depreciation & Amortization | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B |
| Deferred Income Tax | (1.39B) | (2.74B) | (3.29B) | (2.09B) | (965M) |
| Stock-Based Compensation | 583M | 457M | 518M | 507M | 553M |
| Change in Working Capital | (1.26B) | (2.23B) | (1.91B) | 810M | (455M) |
| Accounts Receivables | (1.05B) | (663M) | (995M) | 264M | (295M) |
| Inventory | 13M | (69M) | (751M) | (486M) | (184M) |
| Accounts Payables | 245M | 109M | 198M | 184M | (2M) |
| Other Working Capital | (465M) | (1.61B) | (366M) | 848M | 26M |
| Other Non-Cash Items | 578M | 955M | 744M | 15.3B | 3.96B |
| Operating Cash Flow | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B |
| Capital Expenditures | (973M) | (1.12B) | (1.21B) | (1.25B) | (1.31B) |
| Acquisitions (Net) | (862M) | (2.98B) | (260M) | (20.72B) | (2.87B) |
| Purchases of Investments | (5.48B) | (3.59B) | (1.77B) | (769M) | (2B) |
| Sales of Investments | 6.78B | 6.63B | 948M | 1.39B | 2.05B |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (538M) | (1.06B) | (2.3B) | (21.35B) | (4.13B) |
| Debt Repayment | (6.18B) | (5.31B) | 456M | 10.1B | (5.18B) |
| Common Stock Issued | 0 | 0 | 0 | (106M) | (128M) |
| Common Stock Repurchased | (6.29B) | (8B) | (5.16B) | 0 | 0 |
| Dividends Paid | (4.4B) | (4.63B) | (4.74B) | (4.86B) | (5.05B) |
| Other Financing Activities | 641M | 984M | 27M | 0 | 0 |
| Financing Cash Flow | (16.22B) | (16.96B) | (9.42B) | 5.13B | (10.35B) |
| Effect of Forex Changes | (102M) | (33M) | 45M | (137M) | 187M |
| Net Change in Cash | (657M) | (4.99B) | 2.19B | (1.17B) | (137M) |
| Free Cash Flow | 15.23B | 11.95B | 12.65B | 13.94B | 12.85B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.